Remove FDA Approval Remove Manufacturing Remove Recombinant DNA Technology
article thumbnail

Amivantamab by Johnson & Johnson for Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology.

article thumbnail

What is the Difference Between Biologics and Biosimilars?

Pharma Packaging Solutions

Biologics are drug products that are manufactured using materials from living sources. There are a few common types of biologics, including extracted (taken directly from a living system), semi-synthesized (produced with recombinant DNA technology), vaccines, and gene therapies. What are Biosimilars?